A MULTICENTER, 48-WEEK, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS: PHASE 2B

Registry ID
PS0011
Source registry
HEALTH_CANADA
Status
Ongoing
Phase
PHASE2
Study type
INTERVENTIONAL
Sponsor
UCB INC
Start date
2017-01-12
Last update
2016-11-08

Conditions

Related clinical trials

View on source registry